1
Methods and results: We studied prospectively 704 patients with stable CAD.
2
Irrespective of comorbidities, NSTEMI was not associated with worse outcome than stable CAD.
3
However, data regarding its long-term prognostic value in stable CAD are limited and controversial.
4
We determine relationship of HbA1c with severity and outcome in patients with stable CAD.
5
We analysed the impact of PPIs on the prognosis of patients with stable CAD.
6
Most patients who present for evaluation of stable CAD are categorized as low risk by stress testing.
7
However, whether this polymorphism has any effect on the inflammatory process in patients with stable CAD is unclear.
8
We compared miRNAs identified in acute coronary syndrome (ACS) compared with stable CAD and control populations.
9
Methods and results: BRS was assessed in 66 patients with stable CAD by using cross-spectral analysis to measure baroreceptor-mediated R-R interval oscillations.
10
Conclusions: In patients with stable CAD, the numbers of circulating EPCs correlate with the severity of CAD as well as cardiovascular risk factors.
11
In conclusion, elevated IL-6 levels are strongly associated with future cardiac events and mortality in a population with stable CAD during a long-term follow-up.
12
Additional clinical risk factor assessment rather than isolated platelet function-guided approaches should be investigated in future to evaluate personalized antiplatelet therapy in stable CAD-patients.
13
Conclusions: SES stratified based on education level differentiates patients with stable CAD in Poland regarding their risk profile, symptom control and the use of statins.
14
However, there is little contemporary data regarding HR and the use of HR-lowering medications, particularly beta-blockers, among patients with stable CAD in routine clinical practice.
15
The aim of this study was to examine the changes of novel indexes of repolarization in patients with stable CAD who underwent exercise stress testing.
16
The Prevention of Events with Angiotensin Converting Enzyme Inhibition (PEACE) trial randomized 8,290 patients with stable CAD to trandolapril or placebo.
